Prevalence of Tamoxifen Use for Breast Cancer Chemoprevention Among U.S. Women
- 1 February 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 19 (2), 443-446
- https://doi.org/10.1158/1055-9965.epi-09-0930
Abstract
Background: Tamoxifen can reduce the risk of developing invasive estrogen receptor–positive breast cancer by 49%, but it is unknown how many women in the United States are taking tamoxifen for primary prevention of breast cancer. Methods: Data from the years 2000 and 2005 National Health Interview Surveys were analyzed to estimate the prevalence of tamoxifen use among U.S. women for primary chemoprevention of breast cancer. Results: In 2000, ∼0.2% of U.S. women ages 40 to 79 years without a personal history of breast cancer took tamoxifen for chemoprevention (95% confidence interval, 0.13-0.31). In 2005, the prevalence was ∼0.08% (95% confidence interval, 0.03-0.17). Conclusion: The prevalence of tamoxifen use for primary prevention of breast cancer was very low in the years 2000 and 2005. Possible explanations for the low uptake are explored. Cancer Epidemiol Biomarkers Prev; 19(2); 443–6Keywords
This publication has 21 references indexed in Scilit:
- Explanations for side effect aversion in preventive medical treatment decisions.Health Psychology, 2009
- Communicating side effect risks in a tamoxifen prophylaxis decision aid: The debiasing influence of pictographsPatient Education and Counseling, 2008
- Alternate Methods of Framing Information About Medication Side Effects: Incremental Risk Versus Total Risk of OccurrenceJournal of Health Communication, 2008
- “If I’m better than average, then I’m ok?”: Comparative information influences beliefs about risk and benefitsPatient Education and Counseling, 2007
- Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease OutcomesThe NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 TrialJAMA, 2006
- Factors affecting breast cancer risk reduction practices among California physiciansPreventive Medicine, 2005
- Tamoxifen For Breast Cancer Chemoprevention: Low Uptake by High-Risk Women After Evaluation of a Breast LumpAnnals of Family Medicine, 2005
- Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reductionCancer, 2005
- Overview of the main outcomes in breast-cancer prevention trialsThe Lancet, 2003
- Patient Reluctance Toward Tamoxifen Use for Breast Cancer Primary PreventionAnnals of Surgical Oncology, 2001